Macular Atrophy Incidence, Progression, and Visual Acuity Effects in 5-Year Treatment of Neovascular Age-Related Macular Degeneration
BACKGROUND AND OBJECTIVE: Macular atrophy (MA) contributes to declining vision during prolonged anti-vascular endothelial growth factor (VEGF) treatment in neovascular age-related macular degeneration (nAMD) so greater understanding of its incidence, evolution, and impact on visual acuity is merited
Détails bibliographiques
| Publié dans: | Ophthalmic surgery, lasers & imaging retina. - 2013. - 53(2022), 10 vom: 17. Okt., Seite 546-552
|
|---|
| Auteur principal: |
Richardson, Quintin R
(Auteur) |
|---|
| Autres auteurs: |
Zhang, Youning,
Deiner, Michael S,
Wang, Suling T,
Bhisitkul, Jonah M,
Arnold, Benjamin F,
Bhisitkul, Robert B |
|---|
| Format: | Article en ligne
|
|---|
| Langue: | English |
|---|
| Publié: |
2022
|
|---|
| Accès à la collection: | Ophthalmic surgery, lasers & imaging retina
|
|---|
| Sujets: | Journal Article
Research Support, Non-U.S. Gov't
Research Support, N.I.H., Extramural
Angiogenesis Inhibitors
Endothelial Growth Factors
Vascular Endothelial Growth Factor A
Ranibizumab
ZL1R02VT79 |
|---|